Forecast

There is no analyst data available for this company.

News Go to news feed

Thor Medical brings AlphaOne production facility into commercial operation, shares fall after H1 figures

Thor Medical has put its central AlphaOne production facility in Herøya into commercial operation and has begun initial customer deliveries. In the first half of 2026 the company recorded NOK 900,000 in revenue, a negative EBITDA of NOK 33 million and a net loss of NOK 56.8 million. Cash on hand stood at NOK 59.9 million; available credit lines provide a further NOK 40 million. Management confirms its 2026 revenue forecast in the low double-digit millions of NOK and expects EBITDA and cash-flow break-even in 2027. The share fell 3.26% in pre-market trading to $6.83. » More on de.investing.com

Financials

In the last quarter, NORDIC NANOVECTOR NK 0,20 Aktie had revenue of €0 and net profit of €0

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	0	-
EBITDA	0	-

Fundamentals

Metric	Value
Market capitalization	€184.99M
Number of shares	360M
52-week high/low	€0.66 - €0.29
Dividends	No
Beta	-0.23
P/E ratio	-24.13
PEG ratio	2.59
P/B ratio	0.00
P/S ratio	0.00

Company profile

Thor Medical ASA produziert und liefert Alphateilchen-Strahler für die Krebstherapie in Norwegen. Das Unternehmen wurde 2017 gegründet und hat seinen Hauptsitz in Oslo, Norwegen.